We’ve been waiting since 1953, the year chlorpromazine was introduced to the US as a revolutionary treatment for schizophrenia, for an active treatment for tardive dyskinesia that the FDA judged to be effective.
At Psychiatric Times, it has long been our goal to publish cutting-edge information from the frontiers of psychiatry. In this this spirit, we welcome Dr. Thomas G. Schulze, one of the world’s leading experts on psychiatric genetics to our Editorial Board.
Now is the time to be vigilant and active in the advocacy efforts to fund all the terrific new opportunities the 21st Century Cures Act offers. Here are 9 aspects of the law that focus on psychiatric practice and treatment of those with serious mental illnesses.